Diabetic polyneuropathy
Complication of diabetes mellitus affecting peripheral nerves. Presents with paresthesia, pain, and sensory loss in the extremities.
ICD-10 G63.24 drugs
Also known as: Diabetic peripheral neuropathy, DPN
Drugs used for this condition
- BAlpha-lipoic acid (thioctic acid, ALA)Add-on therapy · Antioxidant; cofactor of pyruvate and α-ketoglutarate dehydrogenaseAdjunct therapy for painful diabetic polyneuropathy. AEMPS approves Thiogamma 600 (oral, nregistro 88703; infusion, 90841) in confirmed disease: IV 600 mg/day for 2–3 weeks, then oral maintenance 300–600 mg/day with periodic review. The symptomatic effect is more convincing for a short IV course: the ALADIN and SYDNEY trials and the Mijnhout 2012 meta-analysis showed moderate reduction of pain and paraesthesia. Evidence for long-term oral use is weaker: the 4-year NATHAN 1 trial missed its primary endpoint. EFNS positions the drug as adjunctive, not first-line: first-line options are gabapentin/pregabalin or duloxetine. If pain is severe or ALA does not work after 4–6 weeks, switching therapy with an endocrinologist or neurologist is appropriate.
- BCapsaicinSecond line · Selective TRPV1 agonist, topical analgesic for neuropathic painCapsaicin 8% patch was FDA-approved in 2020 for painful diabetic peripheral polyneuropathy of the feet. NICE CG173 and redGDPS position the patch as second-line after gabapentinoids and duloxetine in patients with localised pain that does not extend above the knee. AEMPS authorised this indication in 2023. Low-dose 0.025–0.075% creams are not included in current recommendations for diabetic neuropathy – evidence quality is low.
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
- CAcetyl-L-carnitineNot recommended · Acetylated ester of L-carnitine; supplement with claimed neurotropic effectIn painful diabetic neuropathy, acetyl-L-carnitine has individual RCTs showing positive effects on pain and nerve fibre regeneration (Sima 2005, pooled analysis of two RCTs with 1257 patients). These data did not enter ADA or Spanish SED guidelines as standard: first line is gabapentinoids, duloxetine, tricyclics. A clinician may consider acetyl-L-carnitine as optional support, never as a replacement for evidence-based neuropathic pain therapy.
- DDeproteinized hemoderivative from calf bloodNot recommended · Other metabolic agents (local classification)A single published RCT (Ziegler 2009) showed a modest improvement in subjective diabetic polyneuropathy symptoms with intravenous administration. The study has not been replicated in independent multicenter work since. International guidelines from ADA 2024 and AAN 2022 on painful diabetic neuropathy do not mention Actovegin; first-line options are pregabalin, gabapentin, duloxetine, and venlafaxine.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit